TY - JOUR
T1 - Epstein-Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2)
AU - Luo, Wen Juan
AU - Takakuwa, Tetsuya
AU - Ham, Maria Francisca
AU - Wada, Naoki
AU - Liu, Angen
AU - Fujita, Shigeki
AU - Sakane-Ishikawa, Emiko
AU - Aozasa, Katsuyuki
N1 - Funding Information:
We thank Dr PW Turker for providing NAB-2 cell lines. We also thank Dr K Takada for providing the EBV BamHI–Nhet fragments. This work was supported by grants from the Ministry of Education, Science, Culture, and Sports, Japan (14031213, 14770073, 15026209, 15406013, 15590340).
PY - 2004/9
Y1 - 2004/9
N2 - Epstein-Barr virus (EBV) initially isolated from the cultured Burkitt lymphoma (BL) cells, is one of the well-known oncogenic virus. The NAB-2 line, which was established from a North American Burkitt's tumor, was indicated to contain one copy of EBV DNA as the integrated form into chromosome 2p13 of the host genome. To demonstrate the integration site of EBV directly, and to clarify the relation between the integration sites and the oncogenes, fragments containing the nucleotide sequence of NAB-2 integration sites were cloned. EBV was integrated via the terminal repeats (TR), and integration sites located in the clone RP11-440P5 on chromosome 2, between two oncogenes, REL and BCL11A, which is apart from approximately 350kbp from each other. Expression level of REL in NAB-2 was increased. The flanking region of chromosome 2 at the bilateral junction sites showed no homology to the junction sites of EBV. The integration site 2p13 overlaps with common fragile site, FRA2E. NAB-2 cells expressed almost all latent genes but LMP-2A that flanks the TR, indicating the type III of latent infection of EBV. Integration event in NAB-2 might alter the regulation of the oncogenes and provide advantage for continuous cell proliferation.
AB - Epstein-Barr virus (EBV) initially isolated from the cultured Burkitt lymphoma (BL) cells, is one of the well-known oncogenic virus. The NAB-2 line, which was established from a North American Burkitt's tumor, was indicated to contain one copy of EBV DNA as the integrated form into chromosome 2p13 of the host genome. To demonstrate the integration site of EBV directly, and to clarify the relation between the integration sites and the oncogenes, fragments containing the nucleotide sequence of NAB-2 integration sites were cloned. EBV was integrated via the terminal repeats (TR), and integration sites located in the clone RP11-440P5 on chromosome 2, between two oncogenes, REL and BCL11A, which is apart from approximately 350kbp from each other. Expression level of REL in NAB-2 was increased. The flanking region of chromosome 2 at the bilateral junction sites showed no homology to the junction sites of EBV. The integration site 2p13 overlaps with common fragile site, FRA2E. NAB-2 cells expressed almost all latent genes but LMP-2A that flanks the TR, indicating the type III of latent infection of EBV. Integration event in NAB-2 might alter the regulation of the oncogenes and provide advantage for continuous cell proliferation.
KW - BCL-11A
KW - Burkitt's lymphoma
KW - Chromosomal integration
KW - Epstein-Barr virus
KW - NAB-2
KW - REL
UR - http://www.scopus.com/inward/record.url?scp=4344659497&partnerID=8YFLogxK
U2 - 10.1038/labinvest.3700152
DO - 10.1038/labinvest.3700152
M3 - Article
C2 - 15241441
AN - SCOPUS:4344659497
SN - 0023-6837
VL - 84
SP - 1193
EP - 1199
JO - Laboratory Investigation
JF - Laboratory Investigation
IS - 9
ER -